D. Lisak

Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

O. Khan, J. Kamholz, R. Lisak, 2001, Multiple sclerosis.

Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

R. Lisak, P. Dore‐Duffy, R. Balabanov, 2001, Clinical Diagnostic Laboratory Immunology.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

C. Bever, L. Weiner, J. Wolinsky, 2000, Multiple Sclerosis.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

J S Wolinsky, J. Wolinsky, P. Narayana, 2001, Multiple sclerosis.